Subscribe to RSS

DOI: 10.1055/s-0045-1807274
Clinicopathological Characteristics and Survival Outcome among Patients with Renal Cell Carcinoma: A Northern Malaysian Experience

Abstract
Background
Renal cell carcinoma (RCC) is the 12th highest cause of cancer mortality in Malaysia with 532 deaths recorded in 2020. This study aims to determine the prognostic significance of the clinicopathological factors among RCC patients at a Malaysian hospital.
Methods
Medical records of 104 patients with confirmed primary RCC who underwent nephrectomy from 2015 to 2020 at our center were retrospectively reviewed. The relationship between clinical and histopathological data and survival was studied using univariate and multivariate Cox regression analyses to determine prognostic significance. Kaplan–Meier and log-rank tests were employed for survival analysis.
Results
The 5-year cancer-specific survival was 71.2% with a median follow-up of 14 months (interquartile range 5–38 months). Symptoms of loin pain (p = 0.004, hazard ratio [HR] 2.9) or anemia (p = 0.001, HR: 3.6), lower body mass index (p = 0.001, HR 0.88), smoking (p = 0.002, HR 3.3), larger tumors (p < 0.001, HR 1.2), nodal involvement (p < 0.001, HR 7.6), higher International Society of Urological Pathology (ISUP) grade (p < 0.001, HR 2.7), and sarcomatoid features (p < 0.001, HR 16.6) have worse prognosis. Multivariate analysis, adjusted for TNM stage, found smoking (p = 0.002, HR 3.3), larger tumor size (p = 0.048, HR 1.1), nodal involvement (p = 0.009, HR 2.8), higher ISUP grade (p = 0.010, HR 2.0), and sarcomatoid histology (p = 0.001, HR 5.8) to be independent prognostic parameters for overall survival.
Conclusion
Detection and treatment of RCC before symptomatic onset or metastases confer a better prognosis. A history of smoking negatively affects survival. Presence of nodal involvement, venous infiltration, or sarcomatoid component in histopathological study was significantly associated with increased mortality.
Ethics of the Study
This study complies with ethical principles outlined in the Declaration of Helsinki and Malaysian Good Clinical Practice Guideline. The study has been registered under the Malaysian National Medical Research Register and obtained ethics approval from the Malaysian Research Ethics Committee.
Publication History
Received: 05 February 2025
Accepted: 11 March 2025
Article published online:
15 April 2025
© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
- 2 Medina-Rico M, Ramos HL, Lobo M, Romo J, Prada JG. Epidemiology of renal cancer in developing countries: Review of the literature. Can Urol Assoc J 2018; 12 (03) E154-E162
- 3 Yap NY, Ng KL, Ong TA. et al. Clinical prognostic factors and survival outcome in renal cell carcinoma patients–a Malaysian single centre perspective. Asian Pac J Cancer Prev 2013; 14 (12) 7497-7500
- 4 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
- 5 Singam P, Ho C, Hong GE. et al. Clinical characteristics of renal cancer in Malaysia: a ten year review. Asian Pac J Cancer Prev 2010; 11 (02) 503-506
- 6 Turco F, Tucci M, Di Stefano RF. et al. Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. Endocr Relat Cancer 2021; 28 (07) R207-R216
- 7 Kim K, Zhou Q, Christie A. et al. Determinants of renal cell carcinoma invasion and metastatic competence. Nat Commun 2021; 12 (01) 5760
- 8 Tacconi EMC, Tuthill M, Protheroe A. Review of adjuvant therapies in renal cell carcinoma: evidence to date. OncoTargets Ther 2020; 13: 12301-12316
- 9 Blum KA, Gupta S, Tickoo SK. et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020; 17 (12) 659-678
- 10 Iacovelli R, Ciccarese C, Bria E. et al. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: a meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer 2020; 136: 195-203
- 11 Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol 2020; 16 (08) 435-451
- 12 Williamson SR, Gill AJ, Argani P. et al. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer. Am J Surg Pathol 2020; 44 (07) e47-e65